Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the ...

A 10-year-old Indiana boy with Crohn's disease recently experienced a dream come true thanks to the Sunshine Foundation.

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

A new study links mitochondrial dysfunction to Crohn’s disease, shifting how scientists approach treatment and opening doors ...

Tampa Bay Lightning forward Michael Eyssimont was diagnosed with Crohn's disease eight years ago at the age of 21. Since then, he's found a way to manage the disease with treatment and a strict diet.

A British study found that virtual chromoendoscopy has a higher neoplasia detection rate than other endoscopic modalities ...

Pediatric patients who adopted and sustained a CD exclusion diet achieved clinical remission and reported improvement in clinical symptoms and fecal calprotectin.

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Larry Sears and Sally Zlotnick Sears recently donated $1 million to the Crohn’s and Colitis Foundation, according to a news release.

Biocon Biologics launches YESINTEK (ustekinumab-kfce), a biosimilar for Crohn's disease, ulcerative colitis, plaque psoriasis ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...